Rebecca Byam
Known title: Chief Financial OfficerCIK: 0001866256
Rebecca Byam's purchase track record
How the stock did after each of Rebecca Byam's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
7
of 8 since June 13, 2022
Stock higher 6 months later
14%
3 months: 38%
Median 6-month return
-32.3%
3 months: -17.6%
Beat the S&P 500
0%
median -28.3% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/22/2026 | HCWB | $20K | -87.4% | pending | — |
| 5/8/2025 | HCWB | $220K | -36.9% | -53.6% | +18.6% |
| 9/6/2023 | HCWB | $61K | -41.8% | -13.8% | +14.3% |
| 6/5/2023 | HCWB | $160K | +13.4% | -35.5% | +6.9% |
| 5/22/2023 | HCWB | $157K | +22.3% | -32.3% | +8.5% |
| 9/12/2022 | HCWB | $117K | -17.6% | -34.5% | -6.2% |
| 8/24/2022 | HCWB | $325K | -17.6% | -25.0% | -3.6% |
| 6/13/2022 | HCWB | $161K | +27.9% | +5.4% | +6.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| HCWB | ▲ Buy | Open Market | 14,235 | $20K | 5/22/2026 | View on chart |
| HCWB | ▲ Buy | Open Market | 8,462 | $220K | 5/8/2025 | View on chart |
| HCWB | ▲ Buy | Grant | 760,714 | $1.1M | 2/20/2024 | View on chart |
| HCWB | ▲ Buy | Option Exercise | 47,249 | $7K | 10/19/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 5,000 | $10K | 9/13/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 5,000 | $10K | 9/12/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 5,000 | $10K | 9/11/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 5,000 | $10K | 9/8/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 5,000 | $10K | 9/7/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 5,000 | $10K | 9/6/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 20,000 | $41K | 6/9/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 4,696 | $10K | 6/8/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 20,000 | $41K | 6/7/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 19,062 | $35K | 6/6/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 20,000 | $33K | 6/5/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 20,000 | $33K | 5/26/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 20,000 | $32K | 5/25/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 20,000 | $32K | 5/24/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 5,036 | $8K | 5/23/2023 | View on chart |
| HCWB | ▲ Buy | Open Market | 33,450 | $51K | 5/22/2023 | View on chart |
| HCWB | ▲ Buy | Option Exercise | 33,750 | $5K | 11/2/2022 | View on chart |
| HCWB | ▲ Buy | Open Market | 15,000 | $39K | 9/14/2022 | View on chart |
| HCWB | ▲ Buy | Open Market | 15,000 | $39K | 9/13/2022 | View on chart |
| HCWB | ▲ Buy | Open Market | 15,000 | $40K | 9/12/2022 | View on chart |
| HCWB | ▲ Buy | Open Market | 10,000 | $26K | 8/31/2022 | View on chart |
| HCWB | ▲ Buy | Open Market | 7,200 | $18K | 8/30/2022 | View on chart |
| HCWB | ▲ Buy | Open Market | 10,000 | $26K | 8/29/2022 | View on chart |
| HCWB | ▲ Buy | Open Market | 10,000 | $25K | 8/26/2022 | View on chart |
| HCWB | ▲ Buy | Open Market | 40,300 | $105K | 8/25/2022 | View on chart |
| HCWB | ▲ Buy | Open Market | 50,000 | $125K | 8/24/2022 | View on chart |
| HCWB | ▲ Buy | Open Market | 58,856 | $145K | 6/14/2022 | View on chart |
| HCWB | ▲ Buy | Open Market | 7,596 | $16K | 6/13/2022 | View on chart |
| HCWB | ▲ Buy | Option Exercise | 27,000 | $4K | 11/23/2021 | View on chart |
| HCWB | ▲ Buy | Open Market | 10,000 | $44K | 8/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
HCW Biologics Included in After-Market Movers List
HCW Biologics was listed among healthcare stocks moving in Friday's after-market session. The stock is currently trading near its 52-week low, with technical indicators showing oversold conditions. This inclusion highlights recent price volatility, though no specific catalyst for the move was detailed in the provided news.
HCW Biologics Included in After-Market Movers List. HCW Biologics was listed among healthcare stocks moving in Friday's after-market session. The stock is currently trading near its 52-week low, with technical indicators showing oversold conditions. This inclusion highlights recent price volatility, though no specific catalyst for the move was detailed in the provided news.